The company, based in Barcelona and a CataloniaBio & HealthTech member, offers CRO (Contract Research Organization) services to main national and international pharmaceutical, biotechnological and medical device companies, is now celebrating its 25th anniversary.

The company began its activity in the area of cardiovascular investigation and soon gained experience in other cutting-edge clinical development areas, accumulating extensive experience in most therapeutic areas and most notably in cardiology, neurology and oncology. Dr. Mariona Cardona founded Anagram with the aim to guarantee high quality clinical research with medical devices and in that way diversified from the research dedicated exclusively to Drugs. “In a sector such as health, and specifically clinical research, progress is rapid and everchanging. The fact that a company founded in 1998 continues to celebrate its anniversary and is a benchmark in this sector is due to the fact that it has undoubtedly known how to quickly adapt to changes and move forward with them”.

Anagram has managed more than 165 clinical studies in which more than 3,300 hospitals and over 87,000 patients have participated. The results of some of the investigations led by Anagram have been published in prestigious journals and have incorporated changes in standard clinical practice, in several indications. Anagram leads research with medical devices in Spain, especially in cardiology and neurology.

Silvia Casellas joined Anagram as Director of Clinical Research and CEO in 2018, bringing in more than 20 years’ experience in leading international projects in multiple indications. As a result, a number of clients showed interest in expanding their clinical trials internationally. The company belongs to the 4CT (For Clinical Trials) group, aimed at offering a 360º service in clinical studies.

The central event of the 25th Anniversary celebration will be held in May in the emblematic Recinte Modernista de Sant Pau, in Barcelona, and will bring together the most prominent representatives of the clinical research sector.